MINNEAPOLIS, Jan. 10, 2025 — Saluda Medical, Inc., a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using a novel closed-loop, dose-control neuromodulation platform, today announced the closing of a $100 million financing.

The financing was led by existing investor Redmile Group, with additional support from existing investors Wellington Management, TPG Life Sciences Innovation, Fidelity Management & Research Company, Action Potential Venture Capital, and funds and accounts advised by T. Rowe Price Associates, Inc. New investor Piper Heartland Healthcare Capital also participated.

Net proceeds from the financing will be used primarily to advance the commercialization of the Evoke® System, the first commercial application of the Company’s proprietary closed-loop, dose-control neuromodulation platform.

The Evoke® System is a physiologic closed-loop, dose-control spinal cord stimulation (SCS) system designed for chronic pain management. Chronic pain affects an estimated 20% of the world’s population, including an estimated 67 million people in the United States alone. Although SCS is a well-established therapy for treating chronic pain, the Evoke® System is the first system designed to sense and measure neural responses to stimulation and automatically adjust therapy to achieve and continuously maintain a targeted level of neural activation. This ensures therapy remains at the patient-specific prescribed level of neural activation, providing more consistent and effective outcomes.

About Saluda Medical
Saluda Medical is a commercial-stage medical device company focused on developing treatments for chronic neurological conditions driven by a novel neuromodulation platform. The Company’s closed-loop, dose-control platform is designed to sense and measure neural responses to stimulation and automatically adjust therapy based on real-time neurophysiological feedback. The Company’s first product, the Evoke® System, is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain, and is designed to treat chronic neuropathic pain by providing spinal cord stimulation (SCS) therapy that senses and measures neural activation to optimize therapy and reduce patient and clinician burden. 12-month results from the EVOKE study, the first and only prospective, multi-center, parallel-arm, double-blind, randomized controlled pivotal study with a voluntary crossover arm in SCS, were published in The Lancet Neurology, 24-month results were published in JAMA Neurology, and 36-month data, demonstrating enduring and consistent pain relief results, were published in Regional Anesthesia and Pain Medicine. To learn more, including risks & important safety information, visit www.saludamedical.com/us/safety/.

Saluda and Evoke are registered trademarks owned by Saluda Medical Pty Ltd. 

Investor Contacts:  
Brian Johnston or Sam Bentzinger
[email protected] 
[email protected]

SOURCE Saluda Medical

Mark Nelson Will Use $100,000 Fellowship to Organize a Nuclear Restart Conference Attended by Key Stakeholders

GREENWICH, Conn., Jan. 10, 2025 — O’Shaughnessy Ventures LLC (OSV), an investment firm that empowers creators, has awarded an O’Shaughnessy Fellowship to Mark Nelson, an energy consultant based in Chicago, Illinois.

Nelson intends to persuade the German people to reverse the decision to decommission the country’s recently closed nuclear power plants. He will organize a conference, bringing together local and international leaders and experts to build trust in the value and feasibility of restarting Germany’s nuclear power program. Nelson will also conduct public opinion polling and travel around Germany visiting nuclear towns and villages. A nuclear restart could, within three years, generate power for millions of Germans and reverse the country’s industrial decline.

Nelson, who holds a Master of Philosophy in nuclear engineering from Cambridge University, has spent 10 years researching and advising on national and international energy systems. He is the founder and managing director of Radiant Energy Group, a consultancy that advises government, nonprofit and industrial clients worldwide on nuclear energy. His analytical work has been covered in The New York Times, The Wall Street Journal and leading European papers.

OSV’s founder and CEO, Jim O’Shaughnessy, commented, “Nuclear energy represents one of our most powerful yet misunderstood tools in combating climate change. Mark combines deep technical expertise with exceptional communication skills, a crucial combination for driving change.”

“German reactors were among the best in the world three short years ago, and German engineers are still the best,” said Nelson. “Restarting the reactors is the fastest way to restore German energy independence while making a better future for Europe.” 

About the Fellowship Program

The O’Shaughnessy Fellowships program, launched in 2023, discovers and empowers the world’s boldest creatives, builders and researchers. Fellows receive a $100,000 grant and access to OSV’s network of founders, investors and experts.

OSV will award 10 Fellowships in 2025. Applicants will also be considered for the O’Shaughnessy Grants program, which provides 20 additional $10,000 grants to promising innovators.

Nelson is the first Fellow of 2025. More information about the 2023 and 2024 Fellows is available on OSV’s website.

Applications for the Fellowships remain open until and including April 30, 2025. Individuals interested in applying can do so via OSV’s website.

About O’Shaughnessy Ventures

OSV is a creative investment firm that empowers and inspires creators to bring their ideas to life. Founded by Jim O’Shaughnessy, a pioneer in quantitative investing, founder of O’Shaughnessy Asset Management, and author of four books on investing, OSV aims to provide financial support and to partner in growing the next life-changing creative ideas.

OSV combines Jim’s deeply rooted interest in all things art, science, investing, and tech with his long-held desire to establish scenarios designed to help promising creators and their inspiring ideas succeed, regardless of age, location, job history, or level of education. For more information, visit www.osv.llc.

Media Contact:
Ena Gong
O’Shaughnessy Ventures LLC
(917) 355-7420
[email protected] 

SOURCE O’Shaughnessy Ventures

• nsave offers trusted dollar, sterling or euro accounts abroad to people from high inflation countries.
• Customers can now access a range of US equities, ETFs and funds.
• TQ Ventures leads $18mn financing, with participation from Sequoia Capital, Y Combinator, ACE Ventures, and Proton.

LONDON and GENEVA, Jan. 10, 2025 — nsave, the provider of trusted, compliant accounts abroad to people from countries with high inflation, has today announced the launch of an investment product, enabling people at risk of financial exclusion to protect and grow their wealth.

The company also confirmed an $18mn Series A investment led by TQ Ventures with participation from Sequoia Capital, Y Combinator, ACE Ventures, and Proton Foundation, to accelerate their growth.

Today’s means customers can access US equities, ETFs and soon funds managed by some of the world’s largest asset managlaunchers via the nsave app, subject to onboarding and compliance checks.

By working with regulated financial institutions and banking partners in the UK and Switzerland, nsave offers safe and compliant accounts abroad, democratising offshore services to millions of people affected by high inflation or economic uncertainty in their home countries.

nsave’s customers include young professionals who move abroad and face exclusionary and outdated compliance processes due to their country of birth, alongside people from high inflation economies, who fear their life savings will be wiped out.

Based in London and Geneva, nsave is led by former Rhodes Scholars Amer Baroudi and Abdallah AbuHashem.

nsave CEO Amer Baroudi said: “Our vision is to go beyond just protecting everyday people’s wealth by enabling safe and compliant accounts abroad, but to enable them to grow it, too.”

“For some of our customers, this is the first time they can access trusted investment services securely. We believe your passport shouldn’t determine your path to prosperity. Our compliance-by-design approach enables us to offer services safely to many more people.” 

TQ Ventures co-founder and co-managing partner, Schuster Tanger, said: “nsave is tapping into a massive market of individuals underserved by existing financial services who need secure, stable financial solutions.”

“From the outset, I was impressed by nsave’s unique approach and the strength of their team, no doubt a function of Amer and Abdallah’s own lived experience of these challenges. We’re thrilled to roll up our sleeves with nsave to create a more inclusive financial system.”

Contact:
[email protected]

Photo: https://mma.prnewswire.com/media/2594677/nsave_Founders_AmerandAbdallah.jpg
Logo: https://mma.prnewswire.com/media/2594678/nsave_Logo.jpg

SOURCE nsave

Mountainfield Venture Partners, a biopharmaceutical company creation firm, partners with Keymed Biosciences to form Timberlyne Therapeutics, accessing global development and commercial rights outside of greater China for CM313

Financing co-led by Abingworth, Bain Capital Life Sciences, and Venrock Healthcare Capital Partners

SAN DIEGO, Jan. 9, 2025 — Timberlyne Therapeutics, a clinical-stage biopharmaceutical company focused on the development of novel therapies for autoimmune disorders, today announced the close of a $180 million Series A financing to advance CM313, a potentially best-in-class monoclonal antibody targeting CD38, for diseases of high unmet medical needs. The financing was led by investors Abingworth, Bain Capital Life Sciences, and Venrock Healthcare Capital Partners, with participation from Boyu Capital, Lilly Asia Ventures, Braidwell LP, and 3H Health Investment. Timberlyne Therapeutics was formed by Mountainfield Venture Partners, a biopharma company creation firm, in partnership with Keymed Biosciences.

Timberlyne has obtained exclusive development and commercialization rights to CM313 worldwide outside of greater China from Keymed Biosciences, a leading drug discovery and development company. Under the terms of the licensing agreement, Keymed will receive an undisclosed upfront payment, as well as future cash milestones, royalties on any potential future net sales, and equity ownership in Timberlyne. Keymed retains development and commercialization rights in greater China.

CM313 is an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity and has been clinically studied across numerous disease states, including immune thrombocytopenic purpura, systemic lupus erythematosus, and relapsed/refractory multiple myeloma. Across these trials, CM313 has demonstrated potentially best-in-class characteristics. The therapeutic potential of CM313 was demonstrated in a clinical study recently published in the New England Journal of Medicine, where the drug candidate achieved a 95% response rate in patients with treatment-refractory Immune Thrombocytopenia.

About Timberlyne Therapeutics

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of transformational therapies for high unmet medical needs. Timberlyne’s lead program is CM313, an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity that targets CD38. By targeting CD38, which is highly expressed on plasma cells, NK cells, and other immune cells, CM313 modulates multiple immune cell types leading to both rapid and durable responses across a range of autoimmune diseases and cancers.

About Keymed Biosciences

Keymed Biosciences Inc. (HKEX: 02162) focuses on the urgent unmet clinical needs, and is committed to providing high-quality, affordable, innovative therapies for patients in China and overseas. Keymed was founded by medical and scientific experts from world-renowned universities who have strong experience in the transformation of scientific and technological achievements to commercialization at home and abroad. The core leadership team includes the inventors of the first PD-1 antibody drugs that were pioneered and approved in the United States and China. The Company was listed on the main board of Hong Kong Stock Exchange on July 8, 2021.

To accelerate the efficiency of our research and discovery, we have established a fully-integrated platform encompassing all of the key functions in the biologic drug development. These include target validation, lead molecule discovery and optimization, preclinical evaluation, process development, translational research, clinical development and manufacturing. This integrated platform has enabled us to rapidly and cost-effectively identify, build, expand and advance our diversified pipeline of innovative and differentiated antibody-based therapies, including monoclonal antibodies, antibody drug conjugates (ADCs) and bispecific antibodies.

About Mountainfield Venture Partners

Mountainfield Venture Partners is a biopharmaceutical company creation firm that builds new companies around development-stage drug candidates with the potential to transform patient care. We form our companies around in-licensed drug candidates, world-class leadership teams, and syndicated capital raises from top-tier life science institutional investors. We also develop the strategy and establish the operations for our companies based on our long track record in biopharmaceutical leadership and operational roles spanning from small start-up biotechnology companies to multi-national pharmaceutical companies.

Contacts

For Timberlyne Therapeutics:

[email protected]

For Mountainfield Venture Partners:

[email protected]

For Media:

[email protected]

SOURCE Timberlyne Therapeutics

NEW YORK, Jan. 9, 2025 — R4 Capital, a national affordable housing tax-credit syndicator, lender, and asset manager, and R4 Capital Funding (R4CF), R4’s tax-exempt lending platform, announced today in 2024 it surpassed $10.6 billion in equity and mortgage financing since inception. This was a significant year marking the most equity closed in a single year, the largest mortgage loan volume closed in a single quarter, and the largest single asset equity investment in the Company’s history.

R4 Capital closed $860 million of equity in 2024 from 50 institutional investors, including 12 new R4 clients. “This is the most capital we have deployed in a single year, which is especially gratifying in lieu of the added challenge of an election year,” noted Jason Gershwin, Managing Director and Director of Fund Management. Since 2012, R4 has raised and manages more than $6.6 billion in LIHTC equity from 138 institutional investors across 37 multi-investor funds and 13 proprietary funds.

In 2024, R4CF provided $691 million of construction and permanent mortgage capital to build or preserve 3,828 units of affordable housing. Remarked R4CF President, James Spound, “2024 represents the platform’s second largest year of capital deployed in our nine-year history. Given the industry-wide challenges of rising interest rates with severe construction cost inflation, our accomplishment speaks to R4’s commitment to providing a highly responsive, streamlined, and creative mortgage platform benefiting both our investor and developer clients.” Since inception in 2016, R4CF has provided more than $4 billion in mortgage loans, financing the construction and preservation of over 24,500 units of affordable housing across 30 states and Washington, DC.

In 2024, R4 successfully closed 56 transactions across all business lines, driven by strong collaborations with both longstanding and new developer partners. This year also marked the closing of R4’s largest LIHTC equity investment to date, for which the Company raised $100 million from six investors to finance the construction of much-needed housing in the heart of Silicon Valley.

2024 is another milestone year for R4 Capital since inception in 2011. The firm is grateful for the shared commitment and ongoing loyalty of its developer and investor partners.

About R4 Capital

R4 Capital is a national affordable housing investor with expertise in LIHTC equity syndication, underwriting, asset management, and tax-exempt lending. Our growing portfolio includes more than 70,000 units of affordable housing.

SOURCE R4 Capital LLC

NEW YORK, Jan. 9, 2025 — Rena Labs, the startup aiming to enable the next generation of autonomous and verifiable AI solutions, has announced the successful closure of a $3.3 million pre-seed funding round led by Paper Ventures. The company attracted investment from a number of high-profile venture capital firms, among them Lightspeed Faction, Eterna Capital, Lyrik Ventures, Mapleblock Capital, Selini Capital, Keyrock, and others.

Responsible for developing the first TEE (Trusted Execution Environment) abstraction middleware, Rena Labs now plans to use the capital to accelerate the development of its groundbreaking TrustEE technology and ensure the privacy, security, and scalability of AI apps. It also intends to expand its team by bringing aboard top developers and industry experts while fostering user education and community engagement around trustless AI.

“This raise marks a pivotal moment in our mission to make user-owned, verifiable AI a reality,” said Conan, co-founder at Rena Labs. “The endorsement of so many proven investors is testament to the culture of innovation that drives us every day. Rena Labs will build a future where AI systems are not just powerful but fundamentally aligned with user privacy and security. This capital allows us to make tremendous strides.”

“We see TEE as being critically important to the evolution of agentic AI, a space with enormous potential, and there’s ample evidence to suggest Rena Labs will be at the center of this transformation,” added Danish Chaudhry, Cofounder of Paper Ventures. “Few projects combine AI with blockchain technology in such a meaningful way, and we are extremely excited to support their vision.”

Rena Labs’ TrustEE abstraction stacks create the foundation for verifiable AI, establishing a trustless intelligence platform accessible to both developers and end users. The company’s high-impact applications will include a Market-Making Integrity Dashboard, Private Order Execution for DEXs, Fully Autonomous AI Agents for On-Chain Gaming, and Private Data Sales in DePIN.

To date, Rena Labs’ collaboration initiatives have spanned multiple domains and include multi-modal large language models (LLMs), autonomous AI agents, DeFi protocols, and innovative applications in gaming and social spheres. Through these efforts, the project aims to deliver impactful, secure, and scalable AI solutions in numerous verticals.

About Rena Labs
Rena Labs is building the first TEE abstraction middleware to supercharge verifiable on-chain AI use cases. Led by a core team that includes Princeton and MIT PhDs, the company empowers developers and retail users to deploy secure AI models with just a few clicks.

Media Contact: [email protected]

SOURCE Rena Labs

WASHINGTON, Jan. 9, 2025 — METIS Intelligence, a global leader in NextGen AI-driven intelligence and law enforcement solutions, has successfully raised a pivotal funding round, led by UAE-based Tau Capital. This new investment will support METIS’ ambitious plans to expand its footprint in North America, making its groundbreaking intelligence solutions accessible to law enforcement, public safety and security agencies of all sizes across the region.

With METIS, these agencies are changing the game, transforming operations, and achieving results by delivering best-in-class intelligence solutions that were previously out of reach, both financially and logistically, especially at the municipal level. Through the power of AI driven smart fusion, cognitive automation and augmented intelligence, METIS enables organizations to harness every available piece of data in “real time”—providing both relevant and actionable insights that dramatically improve the quality of decision making. Making sense of many complex and diverse data sources simultaneously, METIS empowers investigators to quickly uncover critical leads or emerging threats, solve cases faster, and improve the quality of prosecutions.

A significant highlight of this expansion is the appointment of Bill Murray, General Partner at Tau Capital, to the METIS Intelligence Board of Directors. Bill brings decades of global business, ‘Five Eyes’ intelligence, government, and policy experience, which will be instrumental in steering METIS’ growth strategy in North America.”

“This investment is a game-changer for our North American operations,” said Dr. Joseph J. Lestrange, EVP and Chief Strategy and Innovation Officer for METIS North America. “It will accelerate our ability to provide world-class intelligence solutions across the region, that empower agencies to combat crime and adapt quickly to evolving public safety challenges.”

“This investment is a pivotal moment for METIS as we expand our North American operations,” added Natan Bandler, CEO of METIS Intelligence. “With Tau Capital’s backing and our innovative AI technology, we are poised to transform the way agencies of all sizes access and utilize cutting-edge intelligence tools. This milestone aligns with our mission to make advanced technology affordable and impactful for every agency, regardless of size.”

This funding will also fuel METIS’ R&D efforts, enhance partnerships with public and private sectors, and drive the growth of its U.S.-based team, enabling greater responsiveness to the unique needs of North American agencies.

About METIS Intelligence
METIS Intelligence is a cutting-edge AI technology company founded in Israel by intelligence and technology experts. The company’s U.S. operations are based in Washington, DC, and led by former law enforcement and intelligence executives with deep industry expertise. METIS specializes in providing innovative tools that empower professionals to navigate complex challenges, streamline workflows, and deliver impactful results and is uniquely compatible with the complex and diverse tech requirements of the North American market because of its flexible deployment options, including on-prem, gov/private cloud or a SaaS model hosted by METIS!

About Tau Capital
Tau Capital, based in the UAE, invests in transformative technologies that drive innovation and secure a connected future. For more information, visit Tau Capital.

Contact Information:
For media inquiries, please contact:
Dr. Joseph J. Lestrange
EVP / Chief Strategy & Innovation Officer
METIS Intelligence North America
Email: [email protected]

For investor relations inquiries, please contact:
Natan Bandler
CEO METIS Intelligence
Email: [email protected]

SOURCE METIS Intelligence

LOS ANGELES, Jan. 9, 2025 — Phase Four, a leader in advanced in-space propulsion design and manufacturing, announced the first close of its Series C funding round, securing nearly 60% of the target raise with strong participation from new and existing investors. The round is led by Artemis Group Capital, the Oklahoma-based investment firm helmed by former NASA Administrator Jim Bridenstine, underscoring the growing confidence in Phase Four’s innovative propulsion solutions.

“This funding is a pivotal milestone for Phase Four as we scale to meet surging global demand for in-space propulsion from the government and private sector,” said Dr. Umair Siddiqui, Chief Technology Officer at Phase Four. “The supply chain simply isn’t keeping up. With this capital, we’re ramping up production of our Valkyrie family of Hall Effect Thrusters to a minimum of 250 units per year. Simultaneously, we’re advancing next-generation thruster technologies tailored for Defense and National Security customers.”

The growth of Phase Four’s manufacturing capabilities addresses a critical supply-demand gap in the space industry. As the market for small satellite constellations and in-space maneuverability grows exponentially, Phase Four’s propulsion capabilities position the company as a key supplier for commercial and government missions alike.

Phase Four is partnered with Redwire Space (RDW: NYSE) on the Valkyrie propulsion system, reflecting both companies’ view that the market for such thrusters will continue to be robust for the foreseeable future. Combining Phase Four’s technical prowess in the in-space propulsion market with Redwire’s global command of the space system market creates a stable and reliable domestic supplier for a range of high-quality Hall Effect Thrusters.

“We’re proud to scale another U.S. company to the rapidly expanding in-space propulsion market,” said Dr. Steve Kiser, Phase Four’s CEO. “As space-related supply chains around the world face geopolitical and economic risk, having another stable and domestic source for such a critical component of space power is vital.”

The company plans to close its Series C round by the end of Q1 2025, with proceeds aimed at expanding manufacturing, accelerating R&D efforts, and deepening strategic partnerships with key players in the space economy.

About Phase Four 

Phase Four is a disruptive provider of next generation in-space electric propulsion solutions. The company was founded in 2015 to address the demands of the rapid proliferation of satellite constellations and to accelerate the advancement of its radio-frequency thruster. Phase Four is now a full-spectrum in-space electric propulsion provider of hardware, software and services, teaming with a variety of constellation operators and satellite bus manufacturers to optimize mission effectiveness and control costs through creative exploration of propulsion solutions. Learn more at www.phasefour.io. 

About Artemis Group Capital 

Artemis Group Capital is an investment firm specializing in space and defense companies. Led by former NASA Administrator and U.S. Congressman Jim Bridenstine, the firm is focused on advancing national security objectives and supporting transformative technologies for the next generation space economy.   

SOURCE Phase Four, Inc.

Natixis CIB and Advantage Capital provide construction, term debt and tax equity financing for the large-scale solar project coming online in 2025.

MIAMI, Jan. 9, 2025 — Origis Energy, one of America’s leading renewable energy and decarbonization solution platforms, today announced the close of financing for the Swift Air Solar project in Ector County, Texas. The $415 million funding package includes construction, term debt and tax equity financing from Natixis Corporate & Investment Banking (CIB) and Advantage Capital.

Natixis CIB acted as sole coordinating lead arranger, hedging bank, LC issuer, green loan coordinator, and administrative agent for the $290 million construction and term debt financing. Advantage Capital is providing $125 million in tax equity for the project.

Currently under construction, Swift Air Solar will enter commercial production in mid-2025. The project is under agreement with Houston-based Occidental (Oxy) and its subsidiary, 1PointFive, to provide zero-emission solar power for the Direct Air Capture (DAC) facility, STRATOS, currently under construction in the Permian Basin. Origis is the builder, owner, and operator of Swift Air Solar. 

“This is an exciting project, helping to power the world’s first large-scale direct air capture plant. This directly aligns with our mission to supply decarbonization solutions,” said Vikas Anand, Chief Executive Officer, Origis Energy. “A big thank you to Natixis CIB and Advantage Capital for their partnership on Swift Air Solar.”

The Swift Air Solar funding represents the third transaction for Origis and Natixis CIB. The parties worked together on the Origis $750 million construction warehouse facility in August 2023 and an upsize of the Origis $750 million development facility in March 2023.

Nasir Khan, Managing Director, Head of Infrastructure & Energy Finance, Americas said “Natixis CIB is proud to once again partner with Origis Energy on the innovative Swift Air Solar project. This financing, our third with Origis, reinforces our commitment to financing renewable energy solutions that drive the global energy transition. Swift Air’s clean energy contribution to the world’s first large-scale direct air capture plant is a perfect example of the type of innovative and impactful sustainable financing we are dedicated to providing.”

“The Swift Air Solar project highlights what can be achieved when capital, collaboration, and cutting-edge technology come together to drive meaningful impact,” said Tom Bitting, Managing Director at Advantage Capital. “Investing in transformative renewable energy projects like this aligns perfectly with our mission to drive capital to initiatives that foster economic growth and environmental impact. We are proud to support Origis Energy in delivering this innovative clean energy solution, which contributes to accelerating the clean energy transition.”

Latham & Watkins represented Origis Energy in the transaction. Representation for the lenders included Milbank for Natixis CIB and A&O Shearman for Advantage Capital. Local counsel included Reed Smith for Origis and Husch Blackwell representing Natixis CIB and Advantage.

Project information can be found at https://origisenergy.com/project/swift-air/.

About Origis Energy
Origis Energy is accelerating the transition to a carbon-free future by Reimagining Zero^SM. As one of America’s leading renewable energy and decarbonization solution platforms, the company continues to expand and reimagine its contribution to the world’s net-zero goals. Origis Energy puts customers first to deploy a wide range of sustainable solutions for grid power generation and performance, clean hydrogen and long-term operation of solar, energy storage and clean hydrogen plants across the U.S. Founded in 2008, Origis Energy is headquartered in Miami, FL. Learn more at www.origisenergy.com.

About Natixis Corporate & Investment Banking
Natixis Corporate & Investment Banking is a leading global financial institution that provides advisory, investment banking, financing, corporate banking and capital markets services to corporations, financial institutions, financial sponsors and sovereign and supranational organizations worldwide.

Our teams of experts in close to 30 countries advise clients on their strategic development, helping them to grow and transform their businesses, and maximize their positive impact. Natixis CIB is committed to aligning its financing portfolio with a carbon neutrality path by 2050 while helping its clients reduce the environmental impact of their business.

As part of Groupe BPCE, the second largest banking group in France through the Banque Populaire and Caisse d’Epargne retail networks, Natixis CIB benefits from the Group’s financial strength and solid financial ratings (Standard & Poor’s: A+, Moody’s: A1, Fitch: A+, R&I: A+).

About Advantage Capital
Advantage Capital works with renewable energy developers to expand community access to clean energy and invigorate local economies, providing tax-advantaged financing for high-impact renewable energy projects across the U.S. In recent years, the company has invested in over 100 non-residential projects (including C&I, community solar, and utility-scale) in addition to more than 10,000 residential rooftop systems throughout the U.S. and its territories. Since 1992, Advantage Capital has invested more than $4 billion in more than 900 companies from a diverse array of industry sectors and has helped support more than 70,000 jobs. Learn more at Advantagecap.com.

SOURCE Origis Energy